BioStock: Stayble comments on the milestone – 75 percent recruited in phase IIb
Gothenburg-based Stayble Therapeutics recently announced that 75 percent of patients have been enrolled in the clinical phase IIb study with STA363 for chronic discogenic low back pain. BioStock had the opportunity to talk to the company’s CSO Anders Lehmann and VP Business Development Mattias Münnich regarding the milestone and their expectations ahead.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se